Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Therapeutics Acquisition Corp.

Therapeutics Acquisition Corp. (RACA) Stock Overview

Explore Therapeutics Acquisition Corp.’s financial performance, market position, analyst ratings, and future outlook.

RACA●NASDAQ
Financial ServicesShell Companies
$10.27
$0.24(2.44%)
U.S. Market opens in 5h 30m

Therapeutics Acquisition Corp. (RACA)

Meyka AI Score

Z

Key Financials

Market Cap1.1B
P/E Ratio0.00
EPS (TTM)N/A
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

RACA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Therapeutics Acquisition Corp. (NASDAQ: RACA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Therapeutics Acquisition Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RACA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind Therapeutics Acquisition Corp.'s NASDAQ-traded stock include a P/E ratio of 0.00 and a market capitalization of 1.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RACA on the NASDAQ.

Price Performance (NASDAQ: RACA)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
59.54%
3-Year Change
-14.52%
5-Year Change
-14.52%
All-Time (Max) Change
-14.52%

Contact Information

https://researchalliancecorpiii.com
617 778 2500
200 Berkeley Street, Boston, MA, NaN

Company Facts

IPO DateAug 7, 2020
CountryUS

Frequently Asked Questions